Comparison of reduction of blood loss at myomectomy using Misoprostol to that of Haemostatic Torniquet

Comparing Perioperative Vaginal Misoprostol With Intraoperative Pericervical Haemostatic Tourniquet In Reducing Blood Loss During Abdominal Myomectomy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR201802003039106

Enrollment

Registered

2018-02-02

Start date

2016-06-02

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fertility-female Uterine Fibroid

Interventions

Perioperative Vaginal Misoprostol

Pericervical Haemostatic Torniquet

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Diagnosis of uterine fibroid with a treatment plan for abdominal myomectomy

Exclusion criteria

Exclusion criteria: Exclusion criteria: 1.Known allergy to prostaglandins including misoprostol. 2.Chronic medical disorders including hypertension, diabetes mellitus, cardiac or pulmonary diseases. 3.Previous uterine surgery (myomectomy or caesarean section). 4.Known bleeding or clotting disorders. 5.Haematocrit at 24hours before surgery less than 30%. 6.Patient refusal to participate in the study.

Design outcomes

Primary

Measure	Time frame
Intra-operative blood loss andNeed for intra-operative blood transfusion.	—

Secondary

Measure	Time frame
1. Occurrences of side effects of Misoprostol including nausea, vomiting, diarrhoea, shivering and elevated temperature (temperature ¿ 380C). 2. Need for hysterectomy. 3. Post-operative haematocrit. 4. Need for post-operative blood transfusion.	—

Countries

Nigeria

Contacts

Public ContactMUHIBAT AFOLABI

SENIOR REGISTRAR

muhibatafolabi@yahoo.com+234803 819 3027

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026